Clinical trial
Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older…
NCT00303745 · Federation Francophone de Cancerologie Digestive, Other · Unknown status
Key facts
| NCT number | NCT00303745 |
|---|---|
| Title | Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
| Official title | Randomized Study of Second-Line Therapy Comprising Irinotecan With or Without Capecitabine in Patients Aged At Least 75 Years With Colorectal Cancer |
| Lead sponsor | Federation Francophone de Cancerologie Digestive, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, irinotecan hydrochloride |
| Enrollment | 78 |
| Start date | Jun 1, 2006 |
| First posted | Mar 17, 2006 |
| Last update posted | Jul 24, 2008 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: